Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Total Operating Expenses

Total Operating Expenses at other companies

Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$41.37M-12.7%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$10.8M+131%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$57.25M-24.5%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$46.09M-29.3%

Segments

By product

See full
Service Other$4.13M-7.8%

Other financials

Income statement

See full
Revenue-
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$550.99M+783%
Enterprise value$258.93M+455%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029
Line itemTHREE MONTHS ENDED JUNE 30, 2026THREE MONTHS ENDED JUNE 30, 2025SIX MONTHS ENDED JUNE 30, 2026SIX MONTHS ENDED JUNE 30, 2025
Operating expenses:
Research and development (including related party amounts of $13, $27, $26, and $50, respectively)21,92517,86141,23734,914
General and administrative4,9654,94910,08310,068
Total operating expenses26,89022,81051,32044,982
Loss from operations(26,890)(22,810)(51,320)(44,982)
Other income, net:
Interest income1,8861,5612,7983,425
Other (expense) income, net(1)(5)1(8)

Item 1. Financial Statements

FAQ

What is Artiva Biotherapeutics, Inc.'s total operating expenses?
Artiva Biotherapeutics, Inc. (ARTV) reported total operating expenses of $26.89M in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s total operating expenses changed year-over-year?
Artiva Biotherapeutics, Inc.'s total operating expenses increased by 17.9% year-over-year, from $22.81M to $26.89M.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s total operating expenses?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s total operating expenses has grown at a 18.3% compound annual growth rate (CAGR), from $64.16M to $89.81M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Artiva Biotherapeutics, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude